Teva Pharmaceutical Industries Limited (TLV:TEVA)
6,300.00
+48.00 (0.77%)
Oct 26, 2025, 3:54 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $4.18B USD in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.27
Revenue / Employee
$465.95K
Employees
35,686
Market Cap
71.30B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Danel (Adir Yeoshua) | 2.84B |
| Novolog (Pharm-Up 1966) | 2.04B |
| Ilex Medical | 927.57M |
| Kamada | 571.15M |
| InterCure | 243.12M |
| SofWave Medical | 234.12M |
| BrainsWay | 155.27M |
| Bait Bakfar | 106.25M |
Teva Pharmaceutical Industries News
- 3 days ago - IDEV, AER, TEVA, GRAB: ETF Inflow Alert - Nasdaq
- 5 days ago - Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe - Nasdaq
- 6 days ago - Teva (TEVA) Partners with Prestige Biopharma for Tuznue in Europe - GuruFocus
- 6 days ago - Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - GlobeNewsWire
- 9 days ago - Teva Vs. Viatris: Who Will Dominate In President Trump's America? - Seeking Alpha
- 11 days ago - AFI Development - Vedomosti (Ведомости)
- 13 days ago - TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Nasdaq
- 16 days ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq